February 28, 2018 / 10:24 PM / 3 months ago

UPDATE 1-Mylan Q4 earnings fall with EpiPen sales, weak generic prices

(Adds details on quarterly revenue, eanrings forecast)

NEW YORK, Feb 28 (Reuters) - Mylan NV said on Wednesday its fourth-quarter earnings fell due to declining revenue from its EpiPen emergency allergy injector and weak U.S. prices for generic drugs.

The drugmaker reported net income of $244.3 million, or 46 cents a share, in the quarter, down from $417.5 million, or 78 cents a share, last year.

Excluding one-time items, the company said it earned $1.43 a share. Analysts on average were expecting $1.41, according to Thomson Reuters I/B/E/S.

Revenue in the quarter fell 1 percent to $3.24 billion, coming in below the average analyst expectation of $3.3 billion.

Mylan forecast adjusted earnings per share in the range of $5.20 to $5.60 for 2018, in line with analyst estimates. (Reporting by Michael Erman Editing by Chris Reese and Tom Brown)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below